Evidence map›Paper›PMID 41953926›Full record

ArticleJournal of pharmaceutical analysis2026

Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.

Zichang Lin, Zhenghao Deng, Jiahao Liang, Binlong Chen, Yanyan Huang, Bin Liu, Yanzhong Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zichang LinDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Zhenghao DengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410013, China.
Jiahao LiangQingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, Shandong, 266011, China.
Binlong ChenDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Yanyan HuangHealth Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Bin LiuCollege of Biology, Hunan University, Changsha, 410082, China.
Yanzhong ZhaoHealth Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis, a regulated form of cell death characterized by lipid peroxidation (LPO), has emerged as a promising target in cancer therapy. In this study, we detected elevated levels of glutathione (GSH) peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) in human gastric adenocarcinoma tissues, indicating a suppression of ferroptosis in gastric cancer (GC). Apatinib (Apa), a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, was found to induce ferroptosis through the classical SLC7A11/GSH/GPX4 pathway. However, long-term administration of high-dose Apa is associated with adverse side effects and the risk of drug resistance. To address these limitations, we developed a novel drug delivery system (DDSs) using hyaluronic acid (HA)-modified poly (lactic-

Indexed as

ApatinibChi-AgCombination therapyFerroptosisGastric cancer

Identifiers

PMID41953926
PMCPMC13054282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.